You just read:

Takeda Announces Acceptance of European Medicines Agency Submissions for Two Fixed-Dose Combination Therapies, Alogliptin and Pioglitazone and Alogliptin and Metformin, for the Treatment of Type 2 Diabetes

News provided by

Takeda Pharmaceutical Company Limited

19 Jun, 2012, 13:33 BST